Daniel Auclair, President of Hematocure and Senior Vice President of Business Development at Predicta Biosciences, shared a post on X:
“Here’s my annual ASCO26 list of 10 interesting
- MAJESTEC-9
- SUCESSOR-2 MeziKd vs Kd
- InMyCAR updated results
- LINKER-AL2 in AL amyl
- ERASMM Elra in HR SMM”
- Optec/Optal
- BelaDRd in TI NDMM
- IEC-EC in CARTITUDE studies
- Impact of 5-Year Sustained MRD negativity in FORTE
- cfDNA WGS vs Mass Spec
And one bonus thought-provoking on differences in access to CARTs.”
Other articles featuring Daniel Auclair on OncoDaily.